Achyut Healthcare Limited , headquartered in Ahmedabad, Gujarat, has received listing approval from BSE Limited for the issuance of 58,00,000 equity shares of Re.1/- each at a price of Rs.6/- on a preferential basis to both promoters and non-promoters. The approval was communicated by BSE vide letter reference number LOD/PREF/SS/FIP/187/2026-27, dated May 07, 2026. The shares carry a face value of Re.1/- each and are being issued at a premium of Rs.5/-, bringing the total issue price to Rs.6/- per share.

Key Details of the Listing Approval

The listing approval covers a specific range of equity shares, as outlined in the BSE communication. The following table summarises the key parameters of the preferential allotment:

Regulatory Compliance Requirements

BSE has stipulated that trading approval for the aforementioned shares will be granted only upon fulfilment of specific compliance conditions. The company is required to submit the following documents to the Exchange:

• Listing approval from the National Stock Exchange of India Ltd. (if applicable)
• Confirmation letters from NSDL/CDSL confirming the crediting of shares to respective beneficiary accounts or admission of capital into the depository system
• Confirmation letters from NSDL/CDSL regarding lock-in of pre-preferential holdings (if applicable)

The company must also ensure compliance with the provisions of Regulation 167 of SEBI (ICDR) Regulations. Additionally, as per Schedule XIX of the ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, the company is required to apply for trading approval to the stock exchange within seven working days from the date of grant of listing approval. Non-compliance with this requirement will attract fines as specified in the said SEBI circular.

Shareholding Pattern Disclosure

BSE has further noted that in the event the preferential allotment results in a change exceeding two per cent of the total paid-up share capital of the company, Achyut Healthcare Limited will be required to file the updated shareholding pattern in XBRL mode, as mandated under Regulation 31(1)(c) of SEBI LODR Regulations, 2015.

Management Communication

The disclosure was made by Jigen Jagdishbhai Modi, Managing Director of Achyut Healthcare Limited, through a formal communication to BSE Limited. The listing approval letter from BSE was signed by Marian D'souza, Assistant Vice President, and Sahana Shetty, Deputy Manager, on behalf of the Exchange. The company's registered office is located at 504, Iscon Elegance, Circle P, S.G. Highway, Ahmedabad-380 015, Gujarat.

Achyut healthcare has witnessed an increase in promoter shareholding following a preferential allotment of equity shares. Akshit Mahendra Raycha, a promoter of the company, acquired additional shares through this route, as disclosed under SEBI regulations on March 24, 2026.

Share Acquisition Details

The preferential allotment involved 8,00,000 equity shares, representing 0.33% of the company's total share capital. This acquisition was completed on March 23, 2026, with the newly allotted shares ranking pari-passu with existing equity shares having a face value of Re.1 each.

Impact on Company's Share Capital

The preferential allotment resulted in an expansion of Achyut Healthcare's equity base. The company's total equity share capital increased from Rs.23,55,57,000 to Rs.24,13,57,000, comprising 24,13,57,000 equity shares of Re.1 each. This represents the total diluted share capital of the company following the transaction.

Regulatory Compliance

The disclosure was made in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Akshit Mahendra Raycha, identified as belonging to the promoter group, submitted the required documentation to BSE Limited, where the company's shares are listed under scrip code 543499.

Transaction Structure

The acquirer confirmed that no shares were held under encumbrance before or after the transaction, and no voting rights were acquired through instruments other than equity shares. The acquisition strengthens the promoter's stake in the healthcare company, demonstrating continued confidence in the business prospects.